HEMAPHERESIS AND CELLULAR THERAPY

Essay

Submitted for Partial Fulfillment of
The Master Degree in
Clinical and Chemical Pathology
By
Rasha Mohamed Moustafa
M.B.,B.Ch.

Supervised by **Professor Doctor / Nahela Ahmed Shalaby**

Professor of Clinical and Chemical Pathology Faculty of Medicine Ain Shams University

Assistant Professor / Amany Ahmed Osman

Assistant Professor of Clinical and Chemical
Pathology
Faculty of Medicine
Ain Shams University

Faculty of Medicine Ain Shams University 2006

فصادة مكونات الدم و العلاج الخلوي

موضوع رسالة مقدم من

الطبيبة: رشا محمد مصطفى بكالوريوس الطب و الجراحة

توطئة للحصول على درجة الماجستير في الباثولوجيا الاكلينيكية و الكيميائية

تحت اشراف

الأستاذ الدكتور / ناهلة أحمد شلبي

أستاذ الباثولوجيا الاكلينيكية و الكيميائية كلية الطب – جامعة عين شمس

الأستاذ الدكتور / أماني أحمد عثمان

أستاذ مساعد الباثولوجيا الاكلينيكية و الكيميائية كلية الطب - جامعة عين شمس

كلية الطب جامعة عين شمس 2006

<u>Acknowledgement</u>

I would like to express my deepest gratitude and appreciation Professor Dr. Nahela Ahmed Shalaby professor of clinical pathology hematology Faculty of medicine Ain University for her Shams generous supervision help. a n d extreme kindness, spending much of her valuable time advising me. Certainly, her help was more than words can express.

I am very much appreciating and extremely thankful to Dr. Amany Ahmed Osman assistant professor of clinical pathology and hematology faculty of medicine Ain Shams University for her continuous guidance, encouragement and endless support, which aided this work to come to light.

Finally, I would like to record my greatest thanks and gratitude to my

family for their actual help and support received in many ways.

LIST OF ABBREVIATIONS

Abbreviation

2RBC : Double red blood cells

AABB : American Association of Blood Banks

ACD : Acid Citrate Dextrose

ACE : Angiotensin-converting enzyme AChR : Acetylcholine receptor molecule

AD : Air Detector

AFFP : Apheresis Fresh Frozen Plasma

AIDS : Acquired immuno-deficiency syndrome

ALL : Acute lymphocytic leukemiaAML : Acute myelogenous leukemia

ANCAs : Antineutrophil cytoplasmic antibodies

ASFA : American Society for Apheresis

BM : Bone marrow
BP : Blood pumb
C : Centrifugal

CCE : Counterflow centrifugal elutriation

CF : Continuous flow

CFC : Continuous flow centrifugation

CFU-GM : Colony forming units granulocyte macrophages

CFUs : Colony Forming Units

CIC : Circulating immature cells

CIDP : Chronic inflammatory demyelinating polyneuropathy

CLL : Chronic lymphocytic leukemiaCML : Chronic myelogenous leukemia

CMV : Cytomegalovirus

D : Donor

LIST OF ABBREVIATIONS (Cont'd)

DF : Discontinuous FlowDMSO : Dimethylsulfoxide

dsDNA : Double-stranded DNA

ECBV : Extracorporeal blood volume

FACS : Fluorescence-Activated Cell Sorting

FACT : Foundation for the Accreditation of Cellular Therapy

FDA : Food and Drug Administration

FFP : Fresh frozen plasma

g : Gram

G-CSF : Granulocyte-Colony Stimulating Factor G-CSF : Granulocyte Colony-Stimulating Factor

GluR3 : Glutamate receptor

GM-CSF : Granulocyte macrophage colony stimulating factor

GVHD : Graft versus host disease
GVL : Graft-versus-leukemia

Hb A : Hemoglobin AHb S : Hemoglobin SHct : Hematocrit

HDN : Hemolytic disease of the newborn

HES : Hydroxyethyl starch

HLA : Human leukocyte antigenHPA : Human platelet antigen

HPCs : Hematopoietic progenitor cellsHPCT : Hematopoietic cell transplantation

LIST OF ABBREVIATIONS (Cont'd)

HSCs : Hematopoietic stem cells

HSCT : Hematopoietic stem cell transplantation

IFC : Intermittent flow centrifugation

Ig : Immunoglobulin
IgA : Immunoglobulin A
IgD : Immunoglobulin D
IgG : Immunoglobulin G
IgM : Immunoglobulin M

in : Inch

ISCT : International Society for Cellular Therapy

Kg : Kilogram

L : Liter lb : Pounds

LDL : Low density lipoprotein

LVL : Large volume leukapheresis

MCBC : Multicomponent blood collection

Min. : MinutemL : Milliliter

MNC : Mononuclear cells

MoAbs : Monocolonal antibodies

NR : Disorder not ranked P : Pressure monitor

P : Patient

P.P : Plasma protein

PANDAS : Pediatric autoimmune neuropsychiatric

disorder associated with streptococcus

LIST OF ABBREVIATIONS (Cont'd)

PBPC : Peripheral blood progenitor cell

PCR : Polymerase chain reaction

PC-WBC : Photochemically modified white blood cells

PLAP : Platelets by apheresis

PLT : Platelet

PV : Polycythemia vera QC : Quality Control

RA : Rheumatoid arthritis

RBCP : 1 unit RBCs and one large volume plasma unit

RBCs : Red blood cells

Rh-Ig : Rhesus immunoglobulin

SLE : Systemic lupus erythematosus

SM : Spinning Membrane

SP : Source Plasma

TBV : Total blood volume

TLC : Total leukocytic count

TPE : Therapeutic Plasma Exchange

U/L : Unit per Liter

UCB : Umbilical cord blood

vs. : versus

vWF : von Willebrand factor

WBCs : White blood cellsWBD-FFP : Whole blood fresh-frozen plasma

 μL : Microliter

List of Figures

Figure	Title	Page
(1)	Sedimentation blood sample.	7
(2)	Blood components separated by centrifugation	8
	and selectively removed.	
(3)	Basic scheme of component removal in	13
	hemapheresis procedure.	
(4)	Scheme for selective removal of pathogenic	16
	substance from the patient's plasma.	
(5)	The plasma cell separation device of the	19
	Fenwal autopheresis-C.	
(6)	Cross-section of haemonetics centrifuge bowl	21
	(IFC procedure).	
(7)	Hypothetical depletion of whole body (Ig)	34
	levels by TPE.	
(8)	The sequential development of progenitor cells	93
	and mature cells from stem cells.	
(9)	Stem cell plasticity.	95
(10)	Specific gravity of blood cells.	116
(11)	Buffy coat collection using two-way clamp.	123

List of Tables

Table	Title	Page
(1)	Relative Densities of Plasma and Peripheral	12
	Blood Cellular Components.	
(2)	Hemapheresis devices used for donor	18
	collection and patient therapeutics.	
(3)	Diseases Treated with hemapheresis as shown	27
	in Treatment Categories in AABB and ASFA	
	Guidelines.	
(4)	Estimating blood volume: modified rule of	40
	fives.	
(5)	Plasma volumes exchanged: fraction removed	42
	and remaining.	
(6)	Comparison of Replacement Fluids.	43
(7)	Intensity of treatment categories for TPE.	45
(8)	Indication and intensity of treatment categories	46
	for TPE.	
(9)	Donor reactions.	70
(10)	Apheresis fresh-frozen plasma versus whole	77
	blood drived plasma.	
(11)	Criteria for donation of double red blood cells.	85
(12)	Criteria for red blood cell and plasma donation.	86
(13)	Factors reported to affect the mobilization of	111
	PBPC in autologous transplant patients.	

List of Tables (Cont'd)

Table	Title	Page
(14)	Factors affecting the selection of allogenic	113
	donor	
(15)	Methods of T-Cell Depletion	135
(16)	Possible Indications for Hematopoietic	143
	Transplantation	

<u>Aim of this essay</u>

The aim of this essay is to review the literature of hemapheresis, laying special emphasis on its new techniques and its applications whether in donation, cellular therapy or other recent therapeutic modalities.

Introduction

Hemapheresis is the selective removal of one or more component of the blood (*Pineda and Vamvakas*, 2002). In this procedure, the separation is done by centrifugation or filtration of the blood, then the disease-provoking element of the patient is discarded or the selected component of the donor is collected, while the remainder of the blood components are reinfused into the patient or the donor (*Lazarus and Klein*, 2001).

Hemapheresis can be named according to the component of blood that is separated from the donor or the patient. Accordingly, it includes plasmapheresis, leukapheresis and plateletpheresis. Hemapheresis also includes total plasma exchange with removal of the plasma and replacement with fresh frozen plasma (*McLeod*, 2001).

Recently, with the introduction of new treatment modalities such as advanced cancer therapy and the increasing number of marrow and organ transplants, the need for hemapheresis procedure is rapidly growing, as it allows for a greater yield of the desired component (*Tran et al.*, 2004).

Nowadays, hemapheresis has an important role in clinical medicine by permitting the therapeutic removal of pathological cells or plasma and providing a therapeutic transfusion of donor cells or plasma (*Rock*, 2002). This application may be the primary or the secondary or adjunctive therapy. Both the primary and secondary therapies are considered to be effective and beneficial (*Smith et al.*, 2003).

Furthermore, and with the growing need for circulating hematopoietic progenitor cells in cellular therapy, the efficient use of hemapheresis separators techniques have been developed for selecting progenitor cells from peripheral blood and reducing collection of undesired cells (*Moog*, 2004).

BASIC BACKGROUND OF HEMAPHERESIS

A- Definition and Historical Background

Hemapheresis (also termed apheresis) is derived from a Greek verb means "to take away or withdraw" (*Rodwing, 1999 and Lazarus and Klein, 2001*).

It refers to any procedure performed on a donor or patient in which blood is withdrawn from the person and separated ex vivo into some or all of its components. Some of these components are retained for donation or therapeutic purpose and the others are returned to the person (*Gilcher*, 2002).

Hemapheresis practice has an important role in clinical medicine either by permitting the therapeutic removal of pathological cells or plasma (therapeutic hemapheresis), or providing a therapeutic transfusion through administration of donor's cells or plasma collected by hemapheresis (donation hemapheresis). Also, the recent advances in hemapheresis technology help in peripheral blood progenitor cells (PBPCs) collection which is used in cellular therapy (*Klein and David*, 2005).